Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huang, Daniel Q. | - |
dc.contributor.author | Hoang, Joseph K. | - |
dc.contributor.author | Kamal, Rubayet | - |
dc.contributor.author | Tsai, Pei-Chien | - |
dc.contributor.author | Toyoda, Hidenori | - |
dc.contributor.author | Yeh, Ming-Lun | - |
dc.contributor.author | Yasuda, Satoshi | - |
dc.contributor.author | Leong, Jennifer | - |
dc.contributor.author | Maeda, Mayumi | - |
dc.contributor.author | Huang, Chung-Feng | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Ishigami, Masatoshi | - |
dc.contributor.author | Tanaka, Yasuhito | - |
dc.contributor.author | Uojima, Haruki | - |
dc.contributor.author | Ogawa, Eiichi | - |
dc.contributor.author | Abe, Hiroshi | - |
dc.contributor.author | Hsu, Yao-Chun | - |
dc.contributor.author | Tseng, Cheng-Hao | - |
dc.contributor.author | Alsudaney, Manaf | - |
dc.contributor.author | Yang, Ju Dong | - |
dc.contributor.author | Yoshimaru, Yoko | - |
dc.contributor.author | Suzuki, Takanori | - |
dc.contributor.author | Liu, Joanne K. | - |
dc.contributor.author | Landis, Charles | - |
dc.contributor.author | Dai, Chia-Yen | - |
dc.contributor.author | Huang, Jee-Fu | - |
dc.contributor.author | Chuang, Wan-Long | - |
dc.contributor.author | Schwartz, Myron | - |
dc.contributor.author | Dan, Yock Young | - |
dc.contributor.author | Esquivel, Carlos | - |
dc.contributor.author | Bonham, Andrew | - |
dc.contributor.author | Yu, Ming-Lung | - |
dc.contributor.author | Nguyen, Mindie H. | - |
dc.date.accessioned | 2024-07-24T11:00:28Z | - |
dc.date.available | 2024-07-24T11:00:28Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.issn | 1527-7755 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/194921 | - |
dc.description.abstract | PURPOSE There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. METHODS This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and underwent curative surgical resection. The primary outcome was the utilization of antiviral therapy, and the secondary outcome was long-term overall survival (OS). RESULTS The mean (+/- standard deviation [SD]) age was 62.1 (+/- 11.3) years, 74% were male, and 84% were Asian. A total of 47% of the total cohort received antiviral therapy during a mean (+/- SD) follow-up of 5.0 (+/- 4.3) years. The overall antiviral utilization for participants with HBV-related HCC was 57% and declined over time, from 65% before 2010, to 60% from 2010 to 2015, to 47% beyond 2015, P < .0001. The overall utilization of antivirals for HCV-related HCC was 35% and increased over time, from 24% before 2015 to 74% from 2015 and beyond, P < .0001. The 10-year OS was lower in untreated participants for both HBV (58% v 61%) and HCV participants (38% v 82%; both P < .0001). On multivariable Cox regression analysis adjusted for relevant confounders, antiviral therapy initiated before or within 6 months of HCC diagnosis was independently associated with lower mortality in both HBV- (adjusted hazard ratio [aHR], 0.60 [95% CI, 0.43 to 0.83]; P = .002) and HCV-related HCC (aHR, 0.18 [95% CI, 0.11 to 0.31]; P < .0001). CONCLUSION Antiviral therapy is associated with long-term survival in people with HBV- or HCV-related HCC who undergo curative resection but is severely underutilized. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma | - |
dc.title.alternative | Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1200/JCO.23.00757 | - |
dc.identifier.scopusid | 2-s2.0-85186442620 | - |
dc.identifier.wosid | 001233196700012 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.42, no.7, pp 790 - 799 | - |
dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 42 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 790 | - |
dc.citation.endPage | 799 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | RISK | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.